Unraveling Emerging Anal Cancer Clinical Biomarkers from Current Immuno-Oncogenomics Advances

Mol Diagn Ther. 2024 Mar;28(2):201-214. doi: 10.1007/s40291-023-00692-9. Epub 2024 Jan 24.

Abstract

Anal squamous cell carcinoma (ASCC) is a rare gastrointestinal malignancy associated with high-risk human papillomavirus (HPV) and is currently one of the fastest-growing causes of cancer incidence and mortality in developed countries. Although next-generation sequencing technologies (NGS) have revolutionized cancer and immuno-genomic research in various tumor types, a limited amount of clinical research has been developed to investigate the expression and the functional characterization of genomic data in ASCC. Herein, we comprehensively assess recent advancements in "omics" research, including a systematic analysis of genome-based studies, aiming to identify the most relevant ASCC cancer driver gene expressions and their associated signaling pathways. We also highlight the most significant biomarkers associated with anal cancer progression, gene expression of potential diagnostic biomarkers, expression of therapeutic drug targets, and emerging treatment opportunities. This review stresses the urgent need for developing target-specific therapies in ASCC. By illuminating the molecular characteristics and drug-target expression in ASCC, this study aims to provide insights for the development of precision medicine in anal cancer.

Publication types

  • Review

MeSH terms

  • Anus Neoplasms* / diagnosis
  • Anus Neoplasms* / epidemiology
  • Anus Neoplasms* / genetics
  • Biomarkers
  • Carcinoma, Squamous Cell* / diagnosis
  • Carcinoma, Squamous Cell* / genetics
  • Genomics
  • Humans
  • Neoplasm Recurrence, Local / pathology

Substances

  • Biomarkers